Key clinical point: Pirfenidone demonstrated significant efficacy and safety in the treatment of unclassifiable interstitial lung disease.
Major finding: Relative to placebo at 24 weeks, pirfenidone prevented lung function decline as measured with FVC (–17.8 vs. –113.0 mL; P = .002).
Data source: Phase 2 multicenter placebo-controlled, double-blind trial.
Disclosures: Dr. Maher reports no potential conflicts of interest.
Maher TM et al. Lancet Respir Med. 2019 Sep 29. doi: 10.1016/S2213-2600(19)30341-8.